Journal
JOURNAL OF CYSTIC FIBROSIS
Volume 13, Issue 5, Pages 515-519Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jcf.2014.02.004
Keywords
Antibiotic; Staphylococcus aureus; Pseudomonas aeruginosa; Quinolone; Cystic fibrosis
Categories
Funding
- NIH Cardiovascular Interdisciplinary Research Fellowship [HL007121]
- NIH [HL091842]
- Cystic Fibrosis Foundation [R458]
Ask authors/readers for more resources
Background: Ivacaftor increases CFTR channel activity and improves pulmonary function for individuals bearing a G551D mutation. Because ivacaftor structurally resembles quinolone antibiotics, we tested the hypothesis that ivacaftor possesses antibacterial properties. Methods: Bioluminescence, colony forming unit, and minimal inhibitory concentration assays were used to assess viability of Staphylococcus aureus, Pseudomonas aeruginosa and multiple clinical microbial isolates. Results: Ivacaftor induced a dose-dependent reduction in bioluminescence of S. aureus and decreased the number of colony forming units. We observed a similar but less robust effect in P. aeruginosa following outer membrane permeabilization. Ivacaftor inhibited the growth of respiratory isolates of S. aureus and Streptococcus pneumoniae and exhibited positive interactions with antibiotics against lab and respiratory strains of S. aureus and S. pneumoniae. Conclusion: These data indicate that ivacaftor exhibits antibacterial properties and raise the intriguing possibility that ivacaftor might have an antibiotic effect in people with CF. (C) 2014 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available